Rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjunction therewith
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07F-005/02
A61K-031/69
C07K-016/40
C01B-035/10
C01B-035/14
C07K-014/765
C07K-016/28
C07H-021/00
출원번호
US-0694744
(2015-04-23)
등록번호
US-9758533
(2017-09-12)
발명자
/ 주소
Tuttle, Susan Bane
Dilek, Ozlem
Mukherjee, Kamalika
출원인 / 주소
The Research Foundation for The State University of New York
대리인 / 주소
Hoffberg, Esq., Steven M.
인용정보
피인용 횟수 :
0인용 특허 :
45
초록▼
A reaction method comprising combining a carbonyl-substituted arylboronic acid or ester and an α-effect amine in aqueous solution at a temperature between about −5 C to 55 C, and a pH between 2 and 8 to produce an adduct. A process is also provided comprising: contacting a composition having a boron
A reaction method comprising combining a carbonyl-substituted arylboronic acid or ester and an α-effect amine in aqueous solution at a temperature between about −5 C to 55 C, and a pH between 2 and 8 to produce an adduct. A process is also provided comprising: contacting a composition having a boron atom bonded to a sp2 hybridized carbon, the boron having at least one labile substituent, conjugated with a cis-carbonyl, with an α-effect amine, in an aqueous medium for a time sufficient to form an adduct, which may proceed to further products.
대표청구항▼
1. A process comprising: (a) providing:(1) a composition having a boron atom bonded to a sp2 hybridized carbon, conjugated with a cis-carbonyl, and linked to a first moiety, the boron atom having at least one labile substituent, the composition being configured to spontaneously react with an α-effec
1. A process comprising: (a) providing:(1) a composition having a boron atom bonded to a sp2 hybridized carbon, conjugated with a cis-carbonyl, and linked to a first moiety, the boron atom having at least one labile substituent, the composition being configured to spontaneously react with an α-effect amine in an aqueous solvent at −5° C., and, to undergo a replacement of the carbonyl oxygen by formation of a carbon-nitrogen bond in the aqueous solvent; and(2) an α-effect amine, linked to a second moiety, the α-effect amine being configured to spontaneously react with the composition in an aqueous solvent at −5° C., and to undergo replacement of the carbonyl oxygen by the formation of the carbon-nitrogen bond in the aqueous solvent; and(b) contacting the composition with the α-effect amine, in the aqueous solvent at a temperature below about 55° C., to spontaneously form an adduct having an interacting boron of the composition and a nitrogen of the α-effect amine, linking the first moiety and the second moiety,wherein at least one of the first moiety and the second moiety is selected from the group consisting of a probe, a protein, an antibody, a peptide, an amino acid, a nucleic acid, a linker, a drug, a radiolabel, a fluorophore, a sugar, a carbohydrate, a support, a surface, a bead, and a nanoparticle,wherein the composition is: wherein:X1, X2 are groups that can hydrolyze from the boron in the aqueous solvent to yield boronic acid; andR1, R2, and R3 are selected from the group consisting of hydrogen, organic ligands, and heterorganic ligands, and at least one of R1, R2, and R3 are selected from the group consisting of hydrogen, organic ligands, and heterorganic ligands. 2. The process according to claim 1, wherein the contacting is performed at temperatures between about −5° C. to 55° C., and at a pH between 2 and 8, and wherein the composition, the α-effect amine, and the aqueous solvent are biorthogonal and the composition is provided at a concentration of less than or equal to 5 mM. 3. The process according to claim 1, wherein the composition comprises a cis-carbonyl-substituted arylboronic acid or ester. 4. The process according to claim 1, wherein: R1, R2, and R3 are independently selected from the group consisting of H, CH3, C1-C6 alkyl, C1-C6 alkyl which incorporates one further heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur, C2-C6 alkanoyl, CH2Ar, CH2CH2Ar, an aromatic ring, and an aromatic ring substituted with a substituent selected from the group consisting of a fluorescent group, a sugar, and a polyethylene glycol chain, andAr is selected from the group consisting of a phenyl, a substituted phenyl ring, a naphtyl, a heteroaromatic ring, and a fused ring comprising at least one ring heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur. 5. The process according to claim 1, wherein the α-effect amine is selected from the group consisting of: H2N—X3R4,wherein:X3 is O or N; andR4 is an alkyl, aryl or a heteroatom containing group. 6. The process according to claim 5, wherein R4 is selected from the group consisting of: H, CH3, CH2CH3, CH2Ph, p-COOH Ph, o-NH2 Ph, o-OH Ph, COH, COCH3, COCH2Ph, COPh, CO-coumarin, and CONH2. 7. The process according to claim 1, wherein the α-effect amine is selected from the group consisting of an alpha hydrazide of tyrosine, phenylalanine, alanine, beta-alanine, glycine, dimethylglycine, and CBz-serine. 8. The process according to claim 1, wherein the α-effect amine is selected from the group consisting of: a hydrazine; a semicarbazide, a thiosemicarbazide; a hydrazide, a thiohydrazide, a hydroxylamine, an O-alkylhydroxylamine, and an O-arylhydroxylamine. 9. The process according to claim 1, wherein: (a) the α-effect amine is selected from the group consisting of: H2N—X3R4,wherein:X3 is O or N; andR4 is an alkyl, aryl or a heteroatom containing group; and(c) the adduct comprises a composition selected from the group consisting of: and a further product thereof formed through at least one of dehydration, intramolecular reaction, interaction with the solvent, and interaction with a reactive heteroatom in the solvent. 10. The process according to claim 9, wherein the further product comprises a dehydration product selected from the group consisting of: wherein X4 is selected from the group consisting of alkyl, aryl, heteroalkyl, heteroaryl, hydroxyl, and water. 11. The process according to claim 1, wherein the spontaneously formed adduct is selected from the group consisting of a hydrazono arylboronic acid, an imino arylboronic acid, a 3,4-borazaisoquinoline and a 1,2-dihydrobenzo [d][1,2,3]diazaborinin-1-uide. 12. The process according to claim 1, wherein the adduct is selected from the group consisting of: wherein:R2 is H or CH3,R3 and R6 are independently selected from the group consisting of alkyl or OR, wherein R is selected from the group consisting of alkyl, heteroalkyl, heteroaryl, alkylamine, alkylthiol, alkylbromide, arylbromide, C2-C6 alkanoyl, CH2Ar or CH2CH2Ar,in which a heteroatom of the heteroalkyl and heteroaryl is selected from the group consisting of nitrogen, oxygen, and sulfur,the Ar group of CH2Ar or CH2CH2Ar is selected from the group consisting of a phenyl, a substituted phenyl ring, a naphtyl, a heteroaromatic ring, and a fused ring comprising at least one ring heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur, a 4to 7 member ring optionally incorporating one or more heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur, an aromatic ring optionally substituted with a fluorescent group, a sugar, and a polyethylene glycol chain; andR5 is selected from the group consisting of H, CH3, CH2CH3, CH2Ph, Ph, substituted Ph, and NH2. 13. The process according to claim 1, wherein the composition comprises a cis-carbonyl substituted arylboronic acid selected from the group consisting of: an ortho formyl phenylboronic acid or ester derivative;an ortho ketone phenylboronic acid or ester derivative;an ortho aldehyde phenylboronic acid ester derivative of an amino acid;a ketone phenylboronic acid or ester derivative of an amino acid;an ortho aldehyde phenylboronic acid derivatized with an orthogonal reactive functional group; anda ketone phenylboronic acid derivatized with an orthogonal reactive functional group. 14. The process according to claim 1, wherein the aqueous solvent has a pH of about 7, and the spontaneous formation of the adduct is substantially complete within a period of less than about 10 minutes at a temperature of about 25° C., and the composition is present at a concentration of less than or equal to 5 mM. 15. An adduct composition, formed by a process comprising: providing:(a) a composition having a boron atom bonded to a sp2 hybridized carbon, conjugated with a cis-carbonyl, and linked to a first moiety, the boron atom having at least one labile substituent, the composition being configured to spontaneously react in an aqueous solvent at −5° C. with an α-effect amine to undergo replacement of the carbonyl oxygen by formation of a carbon-nitrogen bond in the aqueous solvent,wherein the composition is: wherein:X1, X2 are groups that can hydrolyze from the boron in the aqueous solvent to yield boronic acid; andR1, R2, and R3 are selected from the group consisting of hydrogen, organic ligands, and heterorganic ligands, and at least one of R1, R2, and R3 are selected from the group consisting of hydrogen, organic ligands, and heterorganic ligands; and(b) an α-effect amine, linked to a second moiety, the α-effect amine being configured to spontaneously react in an aqueous solvent at −5° C. with the composition, to undergo the replacement of the carbonyl oxygen and the formation of the carbon-nitrogen bond in the aqueous solvent; andcontacting the composition with the α-effect amine, in the aqueous solvent at a temperature below about 55° C., to spontaneously form an adduct having an interacting boron of the composition and nitrogen of the α-effect amine, linking the first moiety and the second moiety, wherein at least one of the first moiety and the second moiety is selected from the group consisting of a probe, a protein, an antibody, a peptide, an amino acid, a nucleic acid, a linker, a drug, a radiolabel, a fluorophore, a sugar, a carbohydrate, a support, a surface, a bead, and a nanoparticle. 16. The adduct composition according to claim 15, wherein the composition is: the α-affect amine is: and the spontaneously formed adduct is selected from the group consisting of: wherein:X1 and X2 are groups that can hydrolyze from the boron to yield boronic acid;R2 is selected from the group consisting of H and CH3;R3 and R6 are independently selected from the group consisting of H, OH, O-alkyl, O-heteroalkyl, O-heteroaryl, O-alkylbromide, O-arylbromide, O-alkylamine, O-alkylamide, O-alkylthiol, O-alkylthioester, O-C2-C6 alkanoyl, O-CH2Ar, and —CH2CH2Ar, alkyl, aryl, heteroalkyl, heteroaryl, alkylamine, alkylamide and alkylbromide; andR5 is selected from the group consisting of H, —CH3, —CH2CH3, —CH2Ph, Ph, substituted-Ph, and —NH2 in which a heteroatom of the heteroalkyl and heteroaryl is selected from the group consisting of nitrogen, oxygen, and sulfur, andthe Ar group of CH2Ar or CH2CH2Ar is selected from the group consisting of a phenyl, a substituted phenyl ring, a naphtyl, a heteroaromatic ring or fused ring comprising at least one ring heteroatom selected from nitrogen, oxygen and sulfur, a 4 to 7 ring optionally incorporating one or more heteroatoms selected from oxygen, nitrogen or sulfur, an aromatic ring optionally substituted with a fluorescent group, sugars or polyethylene glycol chain. 17. A kit, comprising: (a) a composition linked to a first moiety, having a boron atom bonded to a sp2 hybridized carbon, the boron having at least one labile substituent, conjugated with a cis-carbonyl,wherein the composition is: wherein:X1, X2 are groups that can hydrolyze from the boron in the aqueous solvent to yield boronic acid; andR1, R2, and R3 are selected from the group consisting of hydrogen, organic ligands, and heterorganic ligands, and at least one of R1, R2, and R3 are selected from the group consisting of hydrogen, organic ligands, and heterorganic ligands; and(b) an α-effect amine linked to a second moiety,wherein at least one of the first moiety is selected from the group consisting of a probe, a protein, an antibody, a peptide, an amino acid, a nucleic acid, a linker, a drug, a radiolabel, a fluorophore, a sugar, a carbohydrate, a support, a surface, a bead, and a nanoparticle,the composition and the α-effect amine each being respectively configured to spontaneously react with each other in an aqueous solvent at a temperature below about 55° C. to undergo replacement of the carbonyl oxygen cis-conjugated to the boron, by formation of a carbon-nitrogen bond with the amine nitrogen of the α-effect amine in the aqueous solvent to form an adduct. 18. The kit according to claim 17, wherein: the α-effect amine is selected from the group consisting of: H2N—X3R4,wherein:X3 is O or N; andR4 is an alkyl, aryl or a heteroatom containing group;wherein the composition and α-effect amine are configured to spontaneously form at least one adduct at pH 7, 25° C., in the aqueous solvent selected from the group consisting of: and optionally at least one of:a further product formed from the adduct through dehydration selected from the group consisting of: wherein X4 is selected from the group consisting of alkyl, aryl, heteroalkyl, heteroaryl, hydroxyl and water,a further product formed from the at least one adduct through interaction with the solvent;a further product formed from the at least one adduct through interaction with a reactive heteroatom in the solvent or the adduct. 19. A compound, comprising an anhydrous or hydrated, compound selected from the group consisting of: wherein X═O or NH.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (45)
Lee Ping I. (Berwyn PA), Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentrati.
Urquhart John (Palo Alto CA) Chandrasekaran Santosh Kumar (Palo Alto CA) Shaw Jane Elizabeth (Atherton CA), Bandage for transdermally administering scopolamine to prevent nausea.
Dansereau Richard J. (Sherburne NY) Mosher Russell Y. (Norwich NY) Axelrod Douglas W. (Norwich NY) Sietsema William K. (Norwich NY), Dosage forms of risedronate.
Chandrasekaran Santosh Kumar (Palo Alto CA) Urquhart John (Palo Alto CA) Shaw Jane Elizabeth (Atherton CA), Method and therapeutic system for providing chemotherapy transdermally.
Radebaugh Galen W. (Maple Glen PA) Murtha John L. (Holland PA) Glinecke Robert (Glenside PA), Oral sustained release acetaminophen formulation and process.
Kelm Gary Robert (Cincinnati OH) Manring Gary Lee (Hamilton OH), Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery.
Suzuki Yoshiki (Hino JPX) Ikura Hiroshi (Hino JPX) Yamashita Gentaro (Koganei JPX), Slow-releasing medical preparation to be administered by adhering to a wet mucous surface.
Chandrasekaran Santosh K. (Palo Alto CA) Darda Siegfried (Ingelheim am Rhein CA DEX) Michaels Alan S. (Atherton CA) Cleary Gary W. (Palo Alto CA), Therapeutic system for administering clonidine transdermally.
Davis Roosevelt (27 Lullwater Estate Rd. Atlanta GA 30307) Primo-Davis Susan A. (27 Lullwater Estate Rd. Atlanta GA 30307), Transdermal therapeutic formulation.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.